Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis

References

• AkitaMShibazakiYIzumiM2004Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmiaJ Toxicol Sci29637115018156
   PubMedGoogle Scholar
• AnthonisenNRManfredaJWarrenCPW1987Antibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med1061962043492164
   PubMed Web of Science ®Google Scholar
• BallPMakeB1998Acute exacerbations of chronic bronchitis: an international comparisonChest113Suppl 3199S204S9515893
   PubMed Web of Science ®Google Scholar
• BlasiFLegnaniDLombardoVM1993Chlamydia pneumoniae infection in acute exacerbations of COPDEur Respir J619228425589
   PubMed Web of Science ®Google Scholar
• BlasiFTarsiaPCosentiniR2003Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infectionsExpert Opin Investig Drugs12116577
   PubMed Web of Science ®Google Scholar
• CazzolaMSalvatoriEDionisioP2006Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitisPulm Pharmacol Ther1930716359895
   PubMed Web of Science ®Google Scholar
• ConciaEAllegranziBCiottoliGB2005Penetration of orally administrated Prulifloxacin into human lung tissueClin Pharmacokinet4412879416372826
   PubMed Web of Science ®Google Scholar
• EllerJEdeASchabergT1998Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung functionChest113154289631791
   PubMed Web of Science ®Google Scholar
• FagonJYChastreJTrouilletJL1990Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patientsAm Rev Respir Dis142100482240819
   PubMed Web of Science ®Google Scholar
• FattoreCCipollaGGattiG1998Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteersClin Drug Invest1638792
   Web of Science ®Google Scholar
• GrassiCSalvatoriERosignoliMT2002Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbation of chronic bronchitisRespiration692172212097764
   PubMed Web of Science ®Google Scholar
• KeamSJPerryCM2004PlurifloxacinDrugs6422213415456336
   PubMed Web of Science ®Google Scholar
• LacroixPCrumbVJDurandoL2003Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac riskEur J Pharmacol477697214512100
   PubMed Web of Science ®Google Scholar
• MateraG2006Pharmacologic characteristics of prulifloxacinPulm Pharmacol Ther1920916360331
   PubMed Web of Science ®Google Scholar
• McGuireAIrwinDEFennP2001The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and WalesValue Health4370511705127
   PubMedGoogle Scholar
• MiravitllesMEspinosaCFernandez-LasoE1999Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPDChest11640610424501
   PubMed Web of Science ®Google Scholar
• MogulkocNKarakurtSIsalskaB1999Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infectionAm J Respir Crit Care Med1603495310390424
   PubMed Web of Science ®Google Scholar
• MontanariMPMingoiaMVaraldoPE2001In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolatesAntimicrob Agents Chemother4536161211709353
   PubMed Web of Science ®Google Scholar
• OzakiMKomoriKMatsudaM1996Uptake and intracellular activity’ of NM394, a new quinolone, in human polymorphonuclear (PMN) leukocytesAntimicrob Agents Chemother40739428851603
   PubMed Web of Science ®Google Scholar
• OzakiMMatsudaMTomiiY1991In vivo evaluation of NM441, a new thiazeto-quinoline derivativeAntimicrob Agents Chemother35249691667252
   PubMed Web of Science ®Google Scholar
• PicolloRBrionNGualanoV2003Pharmacokinetics and tolerability of prulifloxacin after single oral administrationArzneimittelforschung53201512705176
   PubMed Web of Science ®Google Scholar
• PratsGRoigCMiroE2002In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolonesEur J Clin Microbiol Infect Dis2132834 Erratum: Eur J Clin Microbiol Infect Dis, 23:42212072950
   PubMed Web of Science ®Google Scholar
• PratsGRossiVSalvatoriE2006Prulifloxacin: a new antibacterial fluoroquinloneExpert Rev Anti Infect Ther4274116441207
   PubMedGoogle Scholar
• ReatoGCuffiniAMTullioV2004Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophilsInt J Antimicrob Agents23150415013040
   PubMed Web of Science ®Google Scholar
• RovetaSSchitoAMMarcheseA2005Microbiological rationale for the utilization of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.Int J Antimicrob Agents263667216216467
   PubMed Web of Science ®Google Scholar
• SethiS2000Infectious etiology of acute exacerbations of chronic bronchitisChest1175 Suppl. 2380S5S10843981
   PubMed Web of Science ®Google Scholar
• SolerNTorresAEwigS1998Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilationAm J Respir Crit Care Med15714985059603129
   PubMed Web of Science ®Google Scholar
• TougouKNakamuraAWatanabeS1998Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a quinolone prodrug prulifloxacin against experimental urinaryDrug Metab Dispos2635599531524
   PubMed Web of Science ®Google Scholar
• TullioVCuffiniAMBoninoA1999Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF3013 against Klebsiella pneumoniae.Drugs Exp Clin Res2511110337499
   PubMedGoogle Scholar
• TullioVCuffiniAMBoninoA2000Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with prulifloxacinJ Antimicrob Chemother46241710933647
   PubMed Web of Science ®Google Scholar
• YoshidaTMitsuhashiS1993Antibacterial activity of NM394, the active form of prodrug NM441, a new quinoloneAntimicrob Agents Chemother377938008388199
   PubMed Web of Science ®Google Scholar